Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here is one cash-producing company that reinvests wisely to drive long-term success and two that may face some trouble.
Two Stocks to Sell:
Hasbro (HAS)
Trailing 12-Month Free Cash Flow Margin: 21.8%
Credited with the creation of toys such as Mr. Potato Head and the Rubik’s Cube, Hasbro (NASDAQ: HAS) is a global entertainment company offering a diverse range of toys, games, and multimedia experiences for children and families.
Why Should You Sell HAS?
- Annual sales declines of 3.5% for the past five years show its products and services struggled to connect with the market
- Subpar operating margin of 9.7% constrains its ability to invest in process improvements or effectively respond to new competitive threats
- Earnings per share lagged its peers over the last five years as they only grew by 2.7% annually
At $93.90 per share, Hasbro trades at 15.4x forward P/E. Dive into our free research report to see why there are better opportunities than HAS.
Enphase (ENPH)
Trailing 12-Month Free Cash Flow Margin: 11.5%
The first company to successfully commercialize the solar micro-inverter, Enphase (NASDAQ: ENPH) manufactures software-driven home energy products.
Why Are We Bearish on ENPH?
- Declining unit sales over the past two years show it’s struggled to increase its sales volumes and had to rely on price increases
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 15.4 percentage points
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
Enphase is trading at $37.42 per share, or 18.6x forward P/E. Check out our free in-depth research report to learn more about why ENPH doesn’t pass our bar.
One Stock to Watch:
ResMed (RMD)
Trailing 12-Month Free Cash Flow Margin: 31.7%
Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE: RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use.
Why Are We Positive on RMD?
- Constant currency growth averaged 9.1% over the past two years, showing it can expand globally regardless of the macroeconomic environment
- Incremental sales over the last five years have been highly profitable as its earnings per share increased by 15.2% annually, topping its revenue gains
- Free cash flow margin grew by 21.4 percentage points over the last five years, giving the company more chips to play with
ResMed’s stock price of $210.98 implies a valuation ratio of 17.8x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
